tiprankstipranks
Trending News
More News >

Hemostemix Accelerates Cell Therapy Production with CytoImmune

Hemostemix Accelerates Cell Therapy Production with CytoImmune

Hemostemix (TSE:HEM) has released an update.

Confident Investing Starts Here:

Hemostemix Inc. has entered into a manufacturing partnership with CytoImmune Therapeutics to produce ACP-01, a cell therapy for severe arterial diseases, in a cutting-edge facility in Puerto Rico. Additionally, Hemostemix has secured $1.8 million in financing, with CytoImmune investing $1.37 million, signifying a strong commitment to the advancement of cell therapy. This strategic move aims to increase production and sales, offering a lifeline to patients facing chronic pain and potential limb amputation.

For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1